In the mouse model, oral DMF treatment in therapeutic as well as in preventive setting ameliorated clinical signs of disease and suppressed frequency of IL-17-producing CD8+ T cells in CNS, consistent with the results obtained from PB of MS patients. The gene discussed is CD8A; the disease is myeloid sarcoma.